GAVRETO Drug Patent Profile

When do Gavreto patents expire, and when can generic versions of Gavreto launch?

Gavreto is a drug marketed by Rigel Pharms and is included in one NDA. There are seven patents protecting this drug.

The generic ingredient in GAVRETO is pralsetinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the pralsetinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Gavreto

Gavreto was eligible for patent challenges on September 8, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 7, 2042. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GAVRETO

US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	41
Patent Applications:	469
Drug Prices:	Drug price information for GAVRETO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GAVRETO
What excipients (inactive ingredients) are in GAVRETO?	GAVRETO excipients list
DailyMed Link:	GAVRETO at DailyMed

See drug prices for GAVRETO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GAVRETO

Constraining patent/regulatory exclusivity:

12,448,366

NDA:

213721

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for GAVRETO

Drug Class	Kinase Inhibitor
Mechanism of Action	Rearranged during Transfection (RET) Inhibitors

US Patents and Regulatory Information for GAVRETO

GAVRETO is protected by eight US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 12,448,366.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes	10,030,005		Y	Y
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes	12,655,128		Y	Y
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes	12,539,303
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes	12,448,366			Y
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes	11,273,160
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes	11,963,958
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes	11,872,192

EU/EMA Drug Approvals for GAVRETO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Gavreto	pralsetinib	EMEA/H/C/005413Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.	Authorised	no	no	no	2021-11-18

International Patents for GAVRETO

When does loss-of-exclusivity occur for GAVRETO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GAVRETO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	106548	INHIBIDORES DE RET
Australia	2016348402
Brazil	112018008877	inibidores de ret
Canada	3003721	INHIBITEURS DE RET POUR LE TRAITEMENT DU CANCER (INHIBITORS OF RET TO TREAT CANCER)
Chile	2018001181	Inhibidores de ret
China	108473468	RET的抑制剂 (INHIBITORS OF RET)
China	111423416	RET的抑制剂 (Inhibitors of RET)

Supplementary Protection Certificates for GAVRETO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3371171	122024000021	Germany		PRODUCT NAME: PRALSETINIB UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON; REGISTRATION NO/DATE: EU/1/21/1555 20211118

Last updated: July 26, 2026

GAVRETO market dynamics and financial trajectory (net sales, pricing, launch drivers, and competitive threats)

Executive summary: GAVRETO (gab?retinib) has moved from initial adoption to steady portfolio contribution, supported by label expansion in metastatic NSCLC harboring RET alterations. Growth has been shaped by (1) uptake in second-line and later settings for RET-driven disease, (2) competition from other RET-directed agents (notably selpercatinib and pralsetinib), (3) dose/safety-driven adherence patterns, and (4) payer formulary dynamics in major oncology franchises. Financial performance is ultimately determined by how quickly GAVRETO captures incremental RET biomarker testing and maintains share against entrenched oral RET competitors with broader or earlier-line penetration in some geographies.

---

What is GAVRETO (gab?retinib) commercial performance and how fast is it growing?

Featured snippet (answer): GAVRETO’s financial trajectory is defined by uptake after initial launches, with subsequent growth tied to RET biomarker diagnosis expansion and label-driven line-of-therapy changes, while share is pressured by competing RET inhibitors.

Key drivers of sales growth

• Tumor biology pull-through: RET alterations in NSCLC and other solid tumors create a defined market anchored to biomarker testing volume, reflex testing adoption, and liquid biopsy penetration.
• Oral tyrosine kinase inhibitor economics: Competitive oral oncology dosing increases convenience and lowers administration friction versus infusion regimens, supporting formulary uptake when cost-effective.
• Line-of-therapy access: Sales acceleration typically follows label expansion into additional treatment lines or eligibility settings where physicians are already using RET inhibitors.
• Safety and adherence: Orally dosed TKIs show sales sensitivity to toxicity management. Establishing predictable dose modifications (neutropenia, liver enzyme elevations, GI events) supports continuity of therapy and reduces early discontinuation.

Key constraints on sales growth

• Competitive substitution: Selpercatinib and pralsetinib can displace gab?retinib when they offer perceived efficacy, tolerability, or earlier-line label access for specific RET-positive subgroups.
• Payer steering: Oncology drug benefit design (prior authorization, step therapy, high cost-sharing tiers) can slow conversion from testing to treatment.
• Testing bottlenecks: RET testing remains uneven by geography and care setting; market penetration correlates with how rapidly centers implement comprehensive genomic profiling (CGP) and reflex RET testing.

---

How does GAVRETO’s revenue trajectory compare with selpercatinib (RETEVMO) and pralsetinib (G?AVRIZO)?

Featured snippet (answer): Relative performance depends on each drug’s geographic and line-of-therapy positioning, plus how payers and clinicians rank tolerability and clinical outcomes for RET-positive populations.

Comparative commercial dynamics

• Share capture mechanics: RET market share is won primarily at the moment of biomarker-driven prescribing. Drugs that are “first tested” and “first chosen” in standard pathways often retain share longer.
• Cross-portfolio influence: Large oncology franchises can expand reach via broader payer coverage strategies and patient support programs.
• Efficacy-to-therapy conversion: Differences in response duration, CNS penetration perceptions, and safety profiles affect physician preference and discontinuation rates, which translate into treatment duration and prescription renewals.

What to watch in competitive metrics

• New starts per month in RET NSCLC (proxy for growth)
• Treatment duration and dose intensity (toxicity management)
• Formulary placement changes across top US commercial plans and large government payers
• Switching rates between RET inhibitors after progression

---

What patents protect GAVRETO and how do they shape market exclusivity?

Featured snippet (answer): Patent protection for gab?retinib governs exclusivity through composition, formulation, and method-of-use coverage; market timing risk for generics hinges on whether ANDA filers can find non-infringing pathways and on whether Orange Book-listed patents remain enforceable.

Patent estate components that typically control enforceability

• Composition-of-matter: Active ingredient and close analogs.
• Crystallography/solid-state forms: Polymorphs, solvates, hydrates.
• Formulation patents: Sustained-release or stability-driven matrix changes, capsule/tablet compositions.
• Method-of-use: Patient selection, line-of-therapy, RET alteration-defined indications, dosing regimens.
• Manufacturing/process patents: Impurities, intermediates, purification conditions.

Practical consequence for generic risk

• If Orange Book listings include strong composition and method-of-use patents tied to RET-positive NSCLC therapy, early generic entry is typically deterred even when partial launch designs exist.

---

When does GAVRETO lose exclusivity (US exclusivity and Orange Book timing)?

Featured snippet (answer): Loss of exclusivity is a function of the last-expiring listed patent and any regulatory exclusivity (including pediatric exclusivity or other term extensions if applicable) that prevents ANDA authorization.

Exclusivity timeline logic used by market participants

• Regulatory exclusivity floor: Fixed periods tied to new chemical entity (NCE) or new indication approvals.
• Patent-driven ceiling: Expiration dates of Orange Book-listed patents, often extending beyond regulatory exclusivity via method-of-use or formulation coverage.
• Patent-by-patent challenge risk: Paragraph IV challenges are generally timed to the earliest patent expiry or to leverage weaker patent claims.

How to model launch risk

• Build a “earliest launch date” grid using:
  • earliest listed patent expiration
  • expected PTA (if any) effects
  • possible pediatric exclusivity extensions
  • settlement structure constraints (see next section)

---

Have generics or biosimilars challenged GAVRETO through Paragraph IV filings?

Featured snippet (answer): The generic entry risk for GAVRETO is tied to whether ANDA filers have challenged specific Orange Book patents; successful challenges can accelerate launch, while settlements can delay it.

Key elements that affect entry outcomes

• Which patents are asserted: Composition, method-of-use, or formulation.
• Infringement theories: Structural equivalence for forms versus method claims anchored to RET-positive treatment.
• At-risk launch constraints: Even with an ANDA approval path, market entry can be blocked by effective injunctions or settlement stay periods.

Settlement-driven market delay

• Parties frequently use settlement agreements to define:
  • agreed “launch date” in exchange for dismissal of litigation
  • royalty structures in some frameworks
  • non-admission clauses and covenant terms

---

What is the FDA regulatory status of GAVRETO and what does it imply for future label growth?

Featured snippet (answer): FDA status influences market trajectory through label scope, post-marketing requirements, and the ability to expand into additional biomarker-defined settings.

Regulatory vectors that move revenue

• New indication approvals: Expand eligible patient pools and increase prescriber adoption.
• Companion diagnostics or testing guidance: Improve conversion of testing to treatment.
• Dose and safety updates: Reduce discontinuation risk and support long-term utilization.

Switching implications for future competitors

• A broadened label can weaken competitor differentiation if it expands patient eligibility beyond niche subsets.
• Conversely, narrow label limitations maintain competitive fragmentation, often benefiting the incumbent(s) with the best payer alignment.

---

Which formulations and dosing regimens are protected for GAVRETO, and can generics design around?

Featured snippet (answer): Formulation and dosing-related patents can create practical barriers for ANDA entrants by increasing development time and raising infringement risk for non-bioequivalent or non-substitutable changes.

Formulation patent categories that matter commercially

• Solid-state and stability: Polymorph or particle size controls that impact shelf life and bioavailability.
• Bioavailability-related composition: Excipients or processing conditions tied to systemic exposure targets.
• Manufacturing impurity controls: Limits on impurities that are critical for regulatory acceptance.

Generic “design-around” feasibility

• Straight reformulation is often constrained by:
  • bioequivalence requirements
  • regulatory chemistry, manufacturing, and controls (CMC) expectations
  • infringement risk on method-of-use and formulation claims

---

What GAVRETO litigation affects market access and timeline?

Featured snippet (answer): Patent litigation affects when generics can launch by controlling court injunctions, stay periods, and settlement-defined entry windows.

How litigation changes the competitive landscape

• Injunction leverage: Even one patent staying enforcement can prevent “at-risk” market entry.
• Settlement economics: Delays can preserve incumbent pricing power and reduce revenue volatility.
• Patent invalidation risk: Court decisions that narrow claims can accelerate future challenges.

Observable indicators for market participants

• Case filings tied to specific Orange Book patents
• Court scheduling milestones
• Settlement press releases that name relevant effective dates for launch

---

How does pricing and payer coverage influence GAVRETO net sales?

Featured snippet (answer): Net sales are sensitive to US commercial and government coverage outcomes, including formulary placement, prior authorization criteria, and net price erosion from discounts, rebates, and competition.

Pricing mechanics that typically shape oncology TKI net revenue

• List price vs net price: High rebate intensity in oncology reduces net sales volatility but compresses margins.
• Payer steering: When RET competitors are preferred, GAVRETO can experience switch pressure and tighter utilization management.
• Patient support programs: Copay assistance can increase persistence among commercially insured patients but can be constrained for high earners or plan design.

International pricing and volume mix

• Territory-level net sales depend on:
  • government tender practices
  • local reimbursement ceilings
  • generics uptake in adjacent drug classes

---

What generic entry risks exist for GAVRETO and what launch scenarios drive revenue exposure?

Featured snippet (answer): The largest revenue exposure comes from a US launch near the first “earliest expiry” date for the most enforceable Orange Book patents and from whether the generic competitor can avoid launch delays through settlements or carve-outs.

Launch scenarios used in revenue stress testing

1. Early challenge success: ANDA entry prior to the broad patent set expiring.
2. Settlement delay: Entry at an agreed later date, often after the earliest asserted patent expires.
3. Partial entry: Limited coverage launches in select geographies with contracting restrictions.
4. Injunction-driven delay: Even with FDA approvals, court stays defer sales.

Downside indicators

• Rapid uptick in generic “at risk” marketing efforts
• Contracting changes that switch dispensing to lower-cost alternatives
• Formulary withdrawals or restriction tightening

---

Which markets are most exposed to competitive substitution for GAVRETO?

Featured snippet (answer): Competitive exposure concentrates in high-testing, high-volume oncology markets with active payer contracting and rapid adoption of RET testing panels.

Market segmentation logic

• US: Strong payer bargaining power and dense provider networks create faster switching dynamics once priced competition emerges.
• EU5 (Germany, France, UK, Italy, Spain): Government and HTA influence determines utilization and price. Tender dynamics can accelerate erosion.
• Japan and other APAC markets: Reimbursement approval pathways and local competition shape uptake pace.

What determines “share stickiness”

• Clinical workflow integration (testing to prescribing)
• Physician familiarity and institution-level prescribing patterns
• Patient support infrastructure and persistence rates

---

What is the overall market size and how does RET-driven NSCLC growth affect GAVRETO?

Featured snippet (answer): GAVRETO’s long-run ceiling tracks the growth of RET-positive NSCLC identification and treatment penetration, offset by competitive substitution within the RET TKI class.

Market growth sources

• Broader CGP adoption: More tumors get profiled for RET alterations.
• Reflex testing protocols: Reduce time-to-treatment and increase conversion.
• Evolving treatment sequencing: RET TKIs used earlier in pathways increase addressable patient pool.

Market headwinds

• Diagnostic drift to multi-gene panels with variant-specific interpretation can slow or accelerate conversion depending on reporting quality.
• Increased use of alternative targeted therapies can siphon patients into other biomarker categories, reducing marginal RET volume growth.

---

Key Takeaways

• GAVRETO’s commercial trajectory is primarily driven by uptake in RET-positive NSCLC as biomarker testing volume expands and label scope supports additional lines of therapy.
• Competitive pressure is structurally high because selpercatinib and pralsetinib are direct RET substitutes with established payer and prescriber familiarity.
• Revenue risk concentrates around Orange Book patent enforceability, Paragraph IV challenge outcomes, and settlement-determined entry windows for ANDA entrants.
• Net sales sensitivity is heavily influenced by payer contracting and rebate structures, not just unit volume.
• Long-term growth depends on sustaining persistence, maintaining formulary access, and capturing incremental patients through RET testing conversion.

---

FAQs

1. What events most often trigger net sales acceleration for GAVRETO?
Label expansions, rapid biomarker testing uptake, and formulary wins that reduce prior authorization barriers.

2. How do adverse event profiles affect long-term GAVRETO revenue?
Toxicity drives dose reductions and discontinuations, which shorten treatment duration and reduce repeat prescribing.

3. What is the highest-impact patent category for preventing generic entry of GAVRETO?
The earliest-expiring Orange Book-listed composition and method-of-use patents tied to RET-positive treatment.

4. What do payer formulary changes usually do to GAVRETO share within the RET inhibitor class?
They can shift prescriptions quickly toward preferred RET TKIs by steering mechanisms, rebates, or restriction criteria.

5. How should investors model GAVRETO downside from ANDA launches?
By using earliest enforceable patent expiry dates, settlement delay probabilities, and expected speed of formulary switching after entry.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and Labeling for GAVRETO (gab?retinib). U.S. Food and Drug Administration.
3. FDA. Guidance for Industry: Paragraph IV Certifications and Patent Certifications Process (relevant FDA documents). U.S. Food and Drug Administration.